Chapter title |
Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease
|
---|---|
Chapter number | 483 |
Book title |
JIMD Reports, Volume 25
|
Published in |
JIMD Reports, January 2015
|
DOI | 10.1007/8904_2015_483 |
Pubmed ID | |
Book ISBNs |
978-3-66-249667-1, 978-3-66-249668-8
|
Authors |
Ozlem Goker-Alpan, Michael J. Gambello, Gustavo H. B. Maegawa, Khan J. Nedd, Daniel J. Gruskin, Larry Blankstein, Neal J. Weinreb, Goker-Alpan, Ozlem, Gambello, Michael J., Maegawa, Gustavo H. B., Nedd, Khan J., Gruskin, Daniel J., Blankstein, Larry, Weinreb, Neal J. |
Abstract |
Agalsidase alfa and agalsidase beta, recombinant enzyme preparations for treatment of Fabry disease (FD), have different approved dosing schedules: 0.2 mg/kg and 1.0 mg/kg every other week (EOW), respectively. This open-label, multicenter, exploratory phase 4 study evaluated plasma globotriaosylsphingosine (lyso-GL-3) and plasma and urine globotriaosylceramide (GL-3) levels at baseline and 2, 4, and 6 months after the switch from agalsidase alfa (0.2 mg/kg EOW for ≥12 months) to agalsidase beta (1.0 mg/kg EOW) in 15 male patients with FD. Immunoglobulin (Ig)G antidrug antibody titers were assessed, and safety was monitored throughout the study. Plasma lyso-GL-3 concentrations decreased significantly within 2 months after switch and reductions continued through month 6 (mean absolute changes, -12.8, -16.1, and -16.7 ng/mL at 2, 4, and 6 months, respectively; all P < 0.001). The mean percentage reduction from baseline was 39.5% (P < 0.001) at month 6. For plasma GL-3, the mean absolute change from baseline (-0.9 μg/mL) and percentage reduction (17.9%) at month 6 were both significant (P < 0.05). Urine GL-3 measurements showed intra-patient variability and changes from baseline were not significant. No clinical outcomes were assessed in this 6-month study, and, therefore, no conclusions can be drawn regarding the correlation of observed reductions in glycosphingolipid concentrations with clinically relevant outcomes. There were no differences in IgG antidrug antibody titers between the two enzymes. The switch from agalsidase alfa to agalsidase beta was well tolerated. Plasma lyso-GL-3 and GL-3 levels reduced after switching from agalsidase alfa to agalsidase beta, indicating that agalsidase beta has a greater pharmacodynamic effect on these markers at the recommended dose. These data further support the use of agalsidase beta 1.0 mg/kg EOW as enzyme replacement therapy in FD. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 3% |
Unknown | 33 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 6 | 18% |
Other | 5 | 15% |
Student > Bachelor | 4 | 12% |
Professor > Associate Professor | 3 | 9% |
Student > Master | 3 | 9% |
Other | 4 | 12% |
Unknown | 9 | 26% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 11 | 32% |
Biochemistry, Genetics and Molecular Biology | 4 | 12% |
Agricultural and Biological Sciences | 3 | 9% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
Nursing and Health Professions | 2 | 6% |
Other | 3 | 9% |
Unknown | 9 | 26% |